Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00408148
Other study ID # RIMON_C_01346
Secondary ID EUDRACT # : 2006
Status Terminated
Phase Phase 3
First received December 5, 2006
Last updated December 9, 2010
Start date October 2006
Est. completion date December 2008

Study information

Verified date December 2010
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Finland: Ethics Committee
Study type Interventional

Clinical Trial Summary

The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.

Primary objectives:

- To assess effect of Rimonabant on HDL ApoA-I fractional catabolic rate (FCR).

Secondary objectives:

- To assess effect of Rimonabant on HDL ApoA-I production rate (PR) and on other lipoprotein kinetics.

- To assess effect of Rimonabant on lipids, glycemic and inflammatory parameters

- To assess effect of Rimonabant on body composition

- To assess safety of Rimonabant


Recruitment information / eligibility

Status Terminated
Enrollment 64
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Both
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria:

- Abdominally obese patients with additional cardiometabolic risk factors

- Females must be post-menopausal

- BMI > 27 kg/m² and < 40 kg/m²

- Men or women with abdominal obesity according to NCEP/ATPIII criteria: Waist Circumference > 88 cm in women; > 102 cm in men

- With at least one lipid abnormality defined as:

- Fasting Triglycerides level > 1.7 mmol/L (150 mg/dL) and < 4.5 mmol/L (400 mg/dL)

- HDL < 1.03 mmol/L (40 mg/dL) in men and < 1.29 mmol/L (50 mg/dL) in women

Exclusion Criteria:

- HDL = 0.60 mmol/L (23 mg/dl)

- Plasma LDL-Cholesterol > 155 mg/dl (4.00 mmol/L) or total cholesterol 250 mg/dl (> 6.5mmol/L) or genetic hyperlipidaemia

- Fasting triglycerides > 400 mg/dL (4.5 mmol/L)

- Known heterozygous or homozygous familial hypercholesterolaemia or know type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia)

- ApoE2/E2 homozygosity, Apo E4/E4 homozygosity

- Type 2 diabetes treated with oral agents and/or insulin

- Diet treated type 2 diabetic patients with HbA1c = 7%

- History of cardio vascular disease

- Systolic blood pressure = 160 mmHg or diastolic blood pressure = 95 mmHg.

- Very low-calorie diet (1200 calories a day or less) or history of surgical procedures for weight loss (e.g., stomach stapling, bypass)

- Body weight fluctuation > 5 Kg during the previous 3 months

- History of bulimia or anorexia nervosa by DSM-IV criteria

- Presence of any clinically significant endocrine disease according to the investigator, Cushing syndrome, obesity secondary to hypothalamic/pituitary disorder.

- Abnormal TSH and free T4 at baseline (Patients treated with thyroid replacement therapy must be on fixed and stable dose for at least 3 months prior to screening and must be in euthyroïd status.)

- Severe hepatic impairment known by the investigator or AST or ALT > 3 times the ULN at screening.

- Known severe renal dysfunction (creatinine clearance < 30 ml/min) or urine analysis (performed at screening by dipstick) showing 2+ or more protein

- Presence of any condition (medical, including clinically significant abnormal laboratory test, psychological, social or geographical) actual or anticipated that the investigator feels would compromise the patient safety or limit his/her successful participation to the study

- Patient treated for epilepsy

- Ongoing major depressive illness

- Uncontrolled psychiatric illness

- History of alcohol and/or drug abuse

- Smoker or smoking cessation within the past 3 months

- Marijuana or hashish users

- Previous participation in a Rimonabant study or to any other clinical trial within 4 weeks to study start

- Hypersensitivity/intolerance to the active substance or to any of the excipients such as lactose

- Blood donation within the past 3 months prior to the study or planned during the study or within the 3 months from the study completing

- Recent history of active peptic ulcer

- Willebrand disease or other hemorrhagic diatheses

- Administration of any of the following within 3 months prior to screening visit and susceptible to be prescribed during the study treatment period:

- Lipid-lowering drugs intake

- Anti obesity drugs

- Other drugs for weight reduction (phentermine, amphetamines)

- Herbal preparations for weight reduction

- Other drugs known to affect lipid metabolism: retinoids, antiretroviral, estrogens and hormone replacement therapy, cyclosporine, glitazones, benfluorex, fish oils, plant sterols.

- Thiazids (including fixed combination) at daily dose higher than 12.5 mg

- Unselective beta-blockers

- Prolonged use (more than one week) of systemic corticosteroids, neuroleptics

- Anticoagulants

- Ongoing antidepressive treatment

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Undistinguishable placebo tablets
Rimonabant
White film-coated, for oral administration containing 20 mg of active rimonabant

Locations

Country Name City State
Australia Sanofi-Aventis Administrative Office North Ryde
Finland Sanofi-Aventis Administrative Office Helsinki
France Sanofi-Aventis Administrative Office Paris
United Kingdom Sanofi-Aventis Administrative Office Guildford

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Countries where clinical trial is conducted

Australia,  Finland,  France,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The fractional catabolic rate (FCR) of HDL ApoA-I After 12 months of treatment. No
Secondary Production Rate (PR) of HDL ApoA-I and A-II, (FCR) of HDL ApoA-II All across the study No
Secondary PR and FCR of VLDL1 and VLDL2 Apo B, VLDL1 and VLDL2 TG, IDL Apo B and LDL Apo B All across the study No
Secondary Variation in ApoA-I, ApoA-II, Lp-AI, Lp-AII, pre-beta-HDL HDL2a, HDL2b, HDL3a, HDL3b, HDL3c, Apo B, Apo C III, TG, LDL-C, HDL-C levels All across the study No
Secondary Variation in Glucose, insulin, HbA1c, leptin, adiponectin All across the study No
Secondary Variation in hs-CRP, TNF-alpha, CETP, PLTP and LCAT activities, lipoprotein and hepatic lipase activities in post-heparin plasma All across the study No
Secondary Variation in whole body fat All across the study No
Secondary Variation in abdominal sub-cutaneous and visceral fat All across the study No
Secondary Variation in liver fat All across the study No
Secondary Variation in blood pressure All across the study No
Secondary Variation in body weight, waist circumference, waist/hip ratio From the beginning to the end of the study No
Secondary CE/TG ratio in HDL All across the study No
Secondary Adverse events From the beginning to the end of the study Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2